This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
·4 min read

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.